Anish Khan¹*, Aishwarya Soni² and Amit Kumar³

¹Centre for Biotechnology, Maharshi Dayanand University, Rohtak-124001, Haryana, India
²Department of Biotechnology, Deenbandhu Chhotu Ram University of Science and Technology-Murthal, Sonepat-131039, Haryana, India
³Assistant Professor, Head of the Department of Zoology, Government College for Women, Gohana-131301, Sonepat, Haryana, India

*Corresponding Author: Anish Khan, Centre for Biotechnology, Maharshi Dayanand University, India. Email: anishkhan9991@gmail.com

Received: June 10, 2021; Published: July 01, 2021

Background

  Corona virus disease-2019 (COVID-19) is a pandemic entity caused by a novel corona virus (severe acute respiratory syndrome-coronavirus-2; SARS-CoV-2), which was firstly documented in Wuhan, Hubei territory in China on December 2019 [1,2]. SARS-CoV-2 is continuing to spread worldwide to till date with a high proportion of infected or affecting ≥10 million individuals globally [1]. Until now, there is no permanent cure for pandemic COVID-19 disease, though a variety of executive options have been evaluated and managed with systemic glucocorticoids for recovery of endurance rate of COVID-19 patients [2]. However, an array of complications reported during and post COVID-19 infection due to extensive use of glucocorticoids, which can lead to secondary fungal co-infection [1,2].

References

1. Sarkar S., et al. "COVID-19 and orbital mucormycosis”. Indian Journal of Ophthalmology4 (2021): 1002.
2. Garg D., et al. "Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature”. Mycopathologia (2021): 1-10
3. Prabhu RM and Robin P. "Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment”. Clinical Microbiology and Infection 10 (2004): 31-47.
4. Skiada A., et al. "Challenges in the diagnosis and treatment of mucormycosis”. Medical Mycology 56 (2018): S93-S101.
5. Jestin M., et al. "Poor outcome associated with mucormycosis in critically ill hematological patients: results of a multicenter study”. Annals of Intensive Care1 (2021): 1-8.
6. Millon L., et al. "Molecular strategies to diagnose mucormycosis”. Journal of Fungi1 (2019): 24.
7. Dadwal SS and Dimitrios PK. "Recent advances in the molecular diagnosis of mucormycosis”. Expert review of Molecular Diagnostics10 (2018): 845-854.
8. Jeong W., et al. "The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports”. Clinical Microbiology and Infection1 (2019): 26-34.
9. Lackner M., et al. "Laboratory diagnosis of mucormycosis: current status and future perspectives”. Future Microbiology5 (2014): 683-695.
10. Kidd SE, et al. "A new age in molecular diagnostics for invasive fungal disease: are we ready?". Frontiers in Microbiology 10 (2020): 2903.

Citation

Citation: Anish Khan., et al. “Mucormycosis: Current Update in Pandemic COVID-19". Acta Scientific Microbiology 4.8 (2021): 01-02.

Copyright

Copyright: © 2021 Anish Khan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.